FR2975007A1 - Composition, useful as a beverage, a food supplement and a sexual stimulant, comprises arginine and saffron - Google Patents

Composition, useful as a beverage, a food supplement and a sexual stimulant, comprises arginine and saffron Download PDF

Info

Publication number
FR2975007A1
FR2975007A1 FR1154127A FR1154127A FR2975007A1 FR 2975007 A1 FR2975007 A1 FR 2975007A1 FR 1154127 A FR1154127 A FR 1154127A FR 1154127 A FR1154127 A FR 1154127A FR 2975007 A1 FR2975007 A1 FR 2975007A1
Authority
FR
France
Prior art keywords
composition
saffron
arginine
beverage
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR1154127A
Other languages
French (fr)
Other versions
FR2975007B1 (en
Inventor
Philippe Davioud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHILIPPE DAVIOUD LAB
Original Assignee
PHILIPPE DAVIOUD LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHILIPPE DAVIOUD LAB filed Critical PHILIPPE DAVIOUD LAB
Priority to FR1154127A priority Critical patent/FR2975007B1/en
Publication of FR2975007A1 publication Critical patent/FR2975007A1/en
Application granted granted Critical
Publication of FR2975007B1 publication Critical patent/FR2975007B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/68—Acidifying substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition comprises arginine and saffron. Independent claims are included for: (1) the preparation of the composition comprising grinding arginine, grinding saffron and mixing ground saffron and arginine; (2) a beverage comprising the composition and a fruit juice; and (3) preparing the beverage comprising diluting the composition in a fruit juice. ACTIVITY : Anabolic. MECHANISM OF ACTION : None given.

Description

La présente invention concerne une composition pour traiter les troubles de la sexualité et en particulier les baisses de tonus sexuel. Elle vise également les boissons obtenues à l'aide de la composition, les compléments alimentaires et leurs utilisations. The present invention relates to a composition for treating disorders of sexuality and in particular decreases in sexual tone. It also relates to beverages obtained using the composition, food supplements and their uses.

Il existe divers troubles de la sexualité, parmi lesquels on peut citer les baisses du tonus sexuel, les diminutions du désir, les troubles causés par la fatigue ou les dysfonctionnements érectiles, ces troubles pouvant être passagers ou chroniques. Or, ces troubles peuvent avoir des conséquences multiples sur la vie d'une personne et de son entourage, telle que la dépression, un manque de confiance en soi, l'isolement et/ou la séparation du couple. L'invention concerne donc une composition visant à remédier aux troubles mentionnés ci-avant. En particulier, l'invention divulgue une composition comportant de l'arginine et du safran. Par « safran », on entend les pistils du crocus sativus, de préférence réduits en poudre. Le safran comporte de nombreuses molécules actives parmi lesquelles le safranal. De préférence, la quantité de safran introduite dans la composition est comprise entre 1 et 8 mg, de préférence entre 1,5 et 6 mg, plus préférentiellement, entre 2 et 4 mg, bornes incluses. Dans toutes la description qui suit, les gammes divulguées doivent être interprétées comme incluant les bornes. L'arginine est préférentiellement introduite dans la composition sous forme de sel(s), par exemple sous forme d'aspartate et/ou de pidolate (ou pyroglutamate) d'arginine, à une quantité comprise entre 2 et 10 g, de préférence entre 3 et 9 g, plus préférentiellement, entre 4 et 8 g. L'arginine peut en particulier se présenter sous la forme des deux sels en combinaison, dans diverses proportions. Avantageusement, le sel d'arginine est finement broyé (de manière à obtenir des tailles de particules inférieures ou égales à 150 micromètres) ou micronisé (de manière à obtenir des tailles de particules inférieures ou égales à 100 micromètres) afin d'augmenter notablement l'activité du sel d'arginine et ainsi d'administrer une dose plus faible pour une activité équivalente. L'arginine est connu pour avoir une action vasodilatatrice par régénération du monoxyde d'azote endogène. Or, une telle action est particulièrement utile pour pallier certains troubles, en particulier les baisses du tonus sexuel, les diminutions du désir, les troubles causés par la fatigue ou les dysfonctionnements érectiles, passagers ou chroniques. En effet, la vasodilatation est une étape clé du mécanisme de la sexualité. Chez la femme, lors de la stimulation sexuelle, il se produit une dilatation du vagin permettant un afflux sanguin appelé 2975007 -2- vasocongestion, tandis que chez l'homme, la dilatation du corps caverneux permet le gonflement de la verge. La combinaison des deux ingrédients de la composition selon l'invention permet d'obtenir une action efficace, assurant à chacun l'assurance d'un acte sexuel bien 5 vécu et accompli. Les effets de la composition selon l'invention sont quasi immédiat chez la femme et apparaissent dans un délai d'une heure chez l'homme. De plus, cette composition ne présente aucun effet secondaire et est préparée à partir d'ingrédients naturels. En particulier, le corps humain est parfaitement apte à éliminer naturellement tout éventuel excès d'un des ingrédients de la composition. 10 C'est pourquoi 2 à 3 prises par jour peuvent être envisagées en fonction des besoins. La composition étant particulièrement efficace chez la femme, on privilégiera l'administration d'une composition présentant une quantité de safran comprise entre 1 et 3 mg et une quantité de sel(s) d'arginine comprise entre 2 et 7 g. 15 Avantageusement, la composition selon l'invention comporte en outre une ou plusieurs huile(s) essentielle(s) d'agrumes. Une telle huile essentielle permet non seulement d'aromatiser la composition mais également de jouer un rôle de conservateur dans la composition. De préférence, la ou les huiles essentielles de la composition sont des huiles essentielles de citron et/ou d'orange et sont introduites 20 à une quantité comprise entre 0,01 et 0,5 mL, de préférence, 0,02 et 0,25 mL, plus préférentiellement encore, entre 0,05 et 0,15 mL. L'invention propose également un procédé de fabrication de la composition selon l'invention comportant les étapes consistant à : broyer l'arginine, 25 broyer le safran, mélanger l'arginine et le safran ainsi broyés. De préférence, l'arginine est sous forme de sel(s), comme indiqué ci-avant. Selon un mode de réalisation préférentiel, les ingrédients sont broyés séparément, de manière à obtenir une poudre dont les particules sont inférieures ou égales à 30 150 micromètres. Avantageusement, le sel d'arginine sera micronisé de manière à obtenir une poudre dont la taille des particules est inférieure ou égale à 100 micromètres. Il est possible d'ajouter ensuite à la composition d'autres ingrédients de manière à modifier le goût de la composition, tel que par exemple une ou plusieurs huiles essentielles, telles que mentionnées ci-avant, et/ou du sucre. 35 Avantageusement, la ou les huiles essentielles seront introduites dans la composition par pulvérisation sur le mélange en poudre. De manière préférentielle, la composition se présente donc sous forme de 2975007 -3- poudre ou de granulés, soluble dans l'eau. Elle peut être ensuite conditionnée sous forme de sachet unidose. De cette façon, la composition peut être aisément conservée, transportée et utilisée. Lors de la prise, il suffit de diluer la composition selon l'invention dans un verre d'eau ou plus préférentiellement dans un jus de 5 fruits. A cet égard, les boissons comportant une composition selon l'invention et un jus de fruits entrent également dans le champ de l'invention. Celle-ci vise par ailleurs, un procédé de préparation d'une boisson par dilution d'une composition selon l'invention dans un jus de fruits. La dissolution de la composition dans le jus de fruits est particulièrement 10 intéressante pour l'obtention des effets recherchés car le jus de fruits présente un apport nutritif complémentaire (teneur en vitamine C, polyphénols, etc .) L'invention concerne enfin l'utilisation d'une composition ou d'une boisson selon l'invention comme complément alimentaire et plus particulièrement comme stimulant sexuel. Avantageusement, chez l'homme le complément alimentaire ou 15 stimulant sexuel sera pris en moyenne une heure avant l'acte sexuel, tandis que chez la femme, celui-ci sera pris seulement quelques minutes avant. L'invention sera mieux comprise à la lecture de l'exemple qui suit, donné à titre illustratif. There are various disorders of sexuality, among which one can cite the decreases of the sexual tone, the decreases of the desire, the troubles caused by the fatigue or the erectile dysfunctions, these disorders being able to be passengers or chronic. However, these disorders can have multiple consequences on the life of a person and his entourage, such as depression, lack of self-confidence, isolation and / or separation of the couple. The invention therefore relates to a composition for remedying the disorders mentioned above. In particular, the invention discloses a composition comprising arginine and saffron. "Saffron" means the pistils of crocus sativus, preferably reduced to powder. Saffron has many active molecules including saffranal. Preferably, the amount of saffron introduced into the composition is between 1 and 8 mg, preferably between 1.5 and 6 mg, more preferably between 2 and 4 mg, inclusive. In all of the following description, the ranges disclosed must be interpreted as including the terminals. The arginine is preferably introduced into the composition in salt form (s), for example in the form of aspartate and / or arginine pidolate (or pyroglutamate), in an amount of between 2 and 10 g, preferably between 3 and 9 g, more preferably between 4 and 8 g. Arginine may in particular be in the form of the two salts in combination, in various proportions. Advantageously, the arginine salt is finely ground (so as to obtain particle sizes less than or equal to 150 microns) or micronized (so as to obtain particle sizes of less than or equal to 100 microns) in order to significantly increase the arginine salt activity and thus administer a lower dose for equivalent activity. Arginine is known to have a vasodilatory action by regeneration of endogenous nitric oxide. However, such action is particularly useful to mitigate certain disorders, in particular the decreases of the sexual tone, the decreases of the desire, the troubles caused by the fatigue or the erectile, passenger or chronic dysfunctions. Indeed, vasodilatation is a key step in the mechanism of sexuality. In women, during sexual stimulation, dilation of the vagina results in a blood flow called vasocongestion, whereas in man, the dilatation of the cavernous body allows the swelling of the penis. The combination of the two ingredients of the composition according to the invention makes it possible to obtain an effective action, assuring everyone the assurance of a well lived and accomplished sexual act. The effects of the composition according to the invention are almost immediate in women and appear within one hour in humans. In addition, this composition has no side effects and is prepared from natural ingredients. In particular, the human body is perfectly capable of naturally eliminating any possible excess of one of the ingredients of the composition. This is why 2 to 3 times a day can be considered depending on the needs. Since the composition is particularly effective in women, preference will be given to administering a composition having a quantity of saffron of between 1 and 3 mg and a quantity of arginine salt (s) of between 2 and 7 g. Advantageously, the composition according to the invention also comprises one or more essential oil (s) of citrus fruits. Such an essential oil not only allows to aromatize the composition but also to play a role of preservative in the composition. Preferably, the essential oil (s) of the composition are essential oils of lemon and / or orange and are introduced in an amount of between 0.01 and 0.5 ml, preferably 0.02 and 0, 25 mL, more preferably between 0.05 and 0.15 mL. The invention also provides a method of manufacturing the composition according to the invention comprising the steps of: grinding the arginine, grinding the saffron, mixing the arginine and saffron and ground. Preferably, the arginine is in the form of salt (s), as indicated above. According to a preferred embodiment, the ingredients are ground separately, so as to obtain a powder whose particles are less than or equal to 150 micrometers. Advantageously, the arginine salt will be micronized so as to obtain a powder whose particle size is less than or equal to 100 microns. It is possible to add other ingredients to the composition so as to modify the taste of the composition, such as for example one or more essential oils, as mentioned above, and / or sugar. Advantageously, the essential oil (s) will be introduced into the composition by spraying the powder mixture. Preferably, the composition is therefore in the form of powder or granules, soluble in water. It can then be packaged as a single dose bag. In this way, the composition can be easily preserved, transported and used. When setting, it is sufficient to dilute the composition according to the invention in a glass of water or more preferably in a fruit juice. In this respect, beverages comprising a composition according to the invention and a fruit juice are also within the scope of the invention. It also relates to a process for preparing a beverage by diluting a composition according to the invention in a fruit juice. The dissolution of the composition in the fruit juice is particularly advantageous for obtaining the desired effects because the fruit juice has a complementary nutrient supply (vitamin C content, polyphenols, etc.) The invention finally relates to the use of a composition or a drink according to the invention as a dietary supplement and more particularly as a sexual stimulant. Advantageously, in humans the dietary supplement or sexual stimulant will be taken on average one hour before the sexual act, while in the woman, it will be taken only a few minutes before. The invention will be better understood on reading the following example, given for illustrative purposes.

20 Exemple 1 : Composition selon l'invention Ingrédients Quantité Aspartate d'arginine 6g Safran poudre 0,0025 g = 2,5 mg Crocus sativus Huile essentielle de citron env. 1 goutte (0,05mL) Huile essentielle d'orange amère env. 1 goutte (0,05mL) Sucre en poudre 1 g Saccharose La composition est préparée selon le procédé suivant : - broyage ou micronisation de l'aspartate d' arginine, 25 - broyage séparé des pistils de crocus sativus, - mélange de l'aspartate d'arginine, du safran et du saccharose, - pulvérisation des huiles essentielles, tout en maintenant le mélange. La composition est ensuite conditionnée sous forme de sachet unidose. EXAMPLE 1 Composition according to the invention Ingredients Quantity Arginine aspartate 6g Saffron powder 0.0025 g = 2.5 mg Crocus sativus Lemon essential oil approx. 1 drop (0.05mL) Bitter orange essential oil approx. 1 drop (0.05 ml) Sugar powder 1 g Sucrose The composition is prepared according to the following process: - grinding or micronization of arginine aspartate, 25 - separate crushing of crocus sativus pistils, - mixture of aspartate arginine, saffron and sucrose, - spraying essential oils, while maintaining the mixture. The composition is then packaged in the form of a single-dose sachet.

FR1154127A 2011-05-12 2011-05-12 COMPOSITION FOR TREATING SEXUALITY DISORDERS Expired - Fee Related FR2975007B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1154127A FR2975007B1 (en) 2011-05-12 2011-05-12 COMPOSITION FOR TREATING SEXUALITY DISORDERS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1154127A FR2975007B1 (en) 2011-05-12 2011-05-12 COMPOSITION FOR TREATING SEXUALITY DISORDERS

Publications (2)

Publication Number Publication Date
FR2975007A1 true FR2975007A1 (en) 2012-11-16
FR2975007B1 FR2975007B1 (en) 2014-03-07

Family

ID=44583124

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1154127A Expired - Fee Related FR2975007B1 (en) 2011-05-12 2011-05-12 COMPOSITION FOR TREATING SEXUALITY DISORDERS

Country Status (1)

Country Link
FR (1) FR2975007B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2995185A1 (en) * 2012-09-13 2014-03-14 Mundema Edible composition, useful as a soothing agent for treating obesity, comprises a flower extract of Crocus sativus having specified particle size and specified safranal content

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059304A1 (en) * 1999-04-02 2000-10-12 Nitromed, Inc. Compositions and methods for preventing and treating sexual dysfunctions
WO2000060939A1 (en) * 1999-04-13 2000-10-19 John Lezdey Lubrication composition
WO2002102163A1 (en) * 2001-06-01 2002-12-27 The Daily Wellness Company Method and composition for enhancing sexual desire
JP2005041812A (en) * 2003-07-22 2005-02-17 Noevir Co Ltd Cell activator
CN101152199A (en) * 2006-09-27 2008-04-02 傅海洋 Health care food for improving sexual function of men and women

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059304A1 (en) * 1999-04-02 2000-10-12 Nitromed, Inc. Compositions and methods for preventing and treating sexual dysfunctions
WO2000060939A1 (en) * 1999-04-13 2000-10-19 John Lezdey Lubrication composition
WO2002102163A1 (en) * 2001-06-01 2002-12-27 The Daily Wellness Company Method and composition for enhancing sexual desire
JP2005041812A (en) * 2003-07-22 2005-02-17 Noevir Co Ltd Cell activator
CN101152199A (en) * 2006-09-27 2008-04-02 傅海洋 Health care food for improving sexual function of men and women

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Vedagara Orgen", 23 May 2011 (2011-05-23), XP002659810, Retrieved from the Internet <URL:http://orgennutra.com/flyers-23may2011/Vedagara%20Flyer23May2011.pdf> [retrieved on 20110921] *
BUYER'S BEST FRIENDS: "Orgen Nutraceuticals Vedagara-Male Sexual", 2010, XP002659806, Retrieved from the Internet <URL:http://www.bbfdirect.com/pp/orgen-nutraceuticals/bbf-14> [retrieved on 20110922] *
DATABASE WPI Week 200518, Derwent World Patents Index; AN 2005-168251, XP002659805 *
DATABASE WPI Week 200872, Derwent World Patents Index; AN 2008-M14540, XP002659807 *
DR. VEENA DEO, B.A.M.S. (M.D.): "Ayurveda, Traditional medicine, Male Impotence, ED", 2010, XP002659809, Retrieved from the Internet <URL:http://www.herbaldestination.com/Natural_Health-Ayurveda,_Traditional_medicine,_Male_Impotence,_ED-200.aspx> [retrieved on 20110921] *
HOSSEINZADEH H ET AL: "The effect of saffron, Crocus sativus stigma, extract and its constituents, safranal and crocin on sexual behaviors in normal male rats", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 15, no. 6-7, 20 June 2008 (2008-06-20), pages 491 - 495, XP022711346, ISSN: 0944-7113, [retrieved on 20071024], DOI: 10.1016/J.PHYMED.2007.09.020 *
MOGHADDASI M S: "Saffron chemicals and medicine usage", JOURNAL OF MEDICINAL PLANT RESEARCH 2010 ACADEMIC JOURNALS NGA, vol. 4, no. 6, 18 March 2010 (2010-03-18), pages 427 - 430, XP002659808, ISSN: 1996-0875 *
SHAMSA A ET AL: "Evaluation of Crocus sativus L. (saffron) on male erectile dysfunction: A pilot study", PHYTOMEDICINE, GUSTAV FISCHER VERLAG, STUTTGART, DE, vol. 16, no. 8, 1 August 2009 (2009-08-01), pages 690 - 693, XP026172688, ISSN: 0944-7113, [retrieved on 20090509], DOI: 10.1016/J.PHYMED.2009.03.008 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2995185A1 (en) * 2012-09-13 2014-03-14 Mundema Edible composition, useful as a soothing agent for treating obesity, comprises a flower extract of Crocus sativus having specified particle size and specified safranal content
WO2015024577A2 (en) 2012-09-13 2015-02-26 Euro Export Sarl Novel safranal-based composition

Also Published As

Publication number Publication date
FR2975007B1 (en) 2014-03-07

Similar Documents

Publication Publication Date Title
US7989007B2 (en) Weight loss composition
JP2019081807A (en) Marine oil formulations comprising resveratrol or derivatives thereof for use in treating, delaying and/or preventing alzheimer&#39;s disease
EP1619962B1 (en) Composition for oral administration containing capsaicinoids
JP2007230870A (en) Brain function ameliorant
FR2975007A1 (en) Composition, useful as a beverage, a food supplement and a sexual stimulant, comprises arginine and saffron
BE1023090B1 (en) COMPOSITION
CN101233927A (en) Hippophae rhamnoides nutrients replenisher
EP2016838B1 (en) Food supplement
FR2938732A1 (en) Nutritive composition, useful for sportsman, preferably for practitioners of physical activity greater than an hour, comprises caffeine, amino acids e.g. leucine, isoleucine and valine, and carbohydrates
EP3027064B1 (en) Pharmaceutical or dietetic or food composition liquid or semi liquid comprising arginine salt deprived of bitterness
JP2007008866A (en) Hypotensive agent composition
EP1708716B1 (en) Oral dieting composition comprising conjugated linoleic acid and caffeine
BE1020033A3 (en) LACTEE BEVERAGE BASED ON PLEUROTE LOVASTATIN.
WO2015024578A1 (en) Novel low-salt food curing agent
AU2011346315B2 (en) Method of intensifying the physiological action of caffeine
JP2012006948A (en) Attaining sexual wellness and health of sexual vascular system with proanthocyanidin
BE1026902B1 (en) MEDICINE AND DIETARY SUPPLEMENT AGAINST GYNECOLOGICAL DISORDERS
FR2861739A1 (en) Alcoholic beverage incorporates active substances such as caffeine, guarana and vitamins to reduce or inhibit negative effects of alcohol
FR3055087B1 (en) FOOD COMPOSITION BASED ON SPIRULINA EXTRACT, FRUIT EXTRACT AND MAGNESIUM
TW201545659A (en) Tomato-containing food or drink
WO2015008101A1 (en) Composition of a drink for enhanced reduction of blood alcohol level
JP2022552311A (en) Improved anti-hangover composition, its preparation and use
BE1021980B1 (en) SLIMMING COMPOSITION.
FR2849601A1 (en) Synergistic, plant extract-based, non-solid oral composition, useful e.g. for reducing weight or stress, contains vitamins and minerals or trace elements to improve bioavailability and efficacy
WO2022020287A1 (en) Compositions for reducing or preventing development of symptoms of alcohol consumption

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20170131